CFIUS completes review of proposed merger of Bayer and Monsanto
(Source: Bayer Company News)
Source: Bayer Company News - December 1, 2017 Category: Pharmaceuticals Source Type: news
Heiko Schipper to join Bayer Board of Management and head Consumer Health Division
Erica Mann to leave Bayer effective March 31, 2018 (Source: Bayer Company News)
Source: Bayer Company News - November 15, 2017 Category: Pharmaceuticals Source Type: news
Bayer and Loxo Oncology to develop and commercialize two novel oncology therapies selectively targeting genetic drivers of cancer (for specialized target groups only)
Larotrectinib (LOXO-101) and LOXO-195 target tropomyosin receptor kinase (TRK) fusion proteins, which are a product of genetic alterations that occur across a range of different tumors / Co-Promotion of the products in the U.S. / Bayer solely responsible for the commercialization of both products outside the U.S. / U.S. filing of larotrectinib planned for late 2017 or early 2018 (Source: Bayer Company News)
Source: Bayer Company News - November 14, 2017 Category: Pharmaceuticals Source Type: news
Bayer submits application for marketing approval of rivaroxaban for patients with coronary or peripheral artery disease to European Medicines Agency (for specialized target groups only)
The rivaroxaban vascular dose, 2.5 mg twice daily plus aspirin 100 mg once daily, demonstrated a 24% reduction in the combined risk of stroke, cardiovascular death and heart attack / The application for marketing approval is based on the COMPASS study / If approved, the rivaroxaban vascular dose, 2.5 mg twice daily plus aspirin low dose once daily, will be the only non-vitamin K antagonist oral anticoagulant (NOAC) indicated for this patient population (Source: Bayer Company News)
Source: Bayer Company News - November 6, 2017 Category: Pharmaceuticals Source Type: news
Bayer receives FDA approval for Xarelto ® 10 mg once daily for the extended treatment of venous thromboembolism (for specialized target groups only)
Rivaroxaban (Xarelto ®) 10 mg once daily significantly reduces the risk of recurrent venous thromboembolism compared with aspirin 100 mg once daily following at least six months of standard anticoagulation therapy / FDA approval based on data from the EINSTEIN CHOICE study (Source: Bayer Company News)
Source: Bayer Company News - October 30, 2017 Category: Pharmaceuticals Source Type: news
Bayer: Sales and earnings increased
Covestro deconsolidated / Group sales grow by 1.2 percent (Fx& portfolio adj.) to EUR 8,025 million / EBITDA before special items up by 4.1 percent to EUR 2,204 million / Sales and earnings growth at Pharmaceuticals / Consumer Health business weak, as expected / Sales gains at Crop Science and Animal Health / Net income of EUR 3,881 million including Covestro book profit / Core earnings per share at EUR 1.47 (minus 3.9 percent) / Group outlook for 2017 confirmed based on change in structure (Source: Bayer Company News)
Source: Bayer Company News - October 26, 2017 Category: Pharmaceuticals Source Type: news
Bayer submits its extended half-life hemophilia A compound for marketing authorization in Japan (for specialized target groups only)
Pivotal studies with BAY94-9027 showed that bleed protection was achieved with extended dosing intervals (Source: Bayer Company News)
Source: Bayer Company News - October 17, 2017 Category: Pharmaceuticals Source Type: news
Bayer signs agreement to sell selected Crop Science businesses to BASF for EUR 5.9 billion
Package includes global glufosinate-ammonium business and selected seeds activities / Assets generated total sales of EUR 1.3 billion in 2016 / Sale is subject to successful closing of Bayer’s acquisition of Monsanto / BASF has committed to maintain employment for all transferring permanent employees for at least three years post closing (Source: Bayer Company News)
Source: Bayer Company News - October 13, 2017 Category: Pharmaceuticals Source Type: news
Bayer cedes control of Covestro
A further 6.9 percent of Covestro shares sold for EUR 1 billion / Control termination agreement reached, effective September 30, 2017 (Source: Bayer Company News)
Source: Bayer Company News - September 29, 2017 Category: Pharmaceuticals Source Type: news
New scholarships worth EUR 417,000 awarded by Bayer Foundation to promote international talents
Highest amount for scholarships since program founding in 1923 / Support for study projects with a focus on science, agriculture, health and teacher training in biology and chemistry / Special programs for vocational careers in technology and health professions as well as for projects with a focus on Africa (Source: Bayer Company News)
Source: Bayer Company News - September 21, 2017 Category: Pharmaceuticals Source Type: news
Crop Science Division of Bayer well positioned to fulfill future customer, market and societal needs
Global seed and crop protection market will continue to grow / Business in Brazil expected to return to normal in 2018 / Progress being made in planned Monsanto acquisition / Anticipated closing in early 2018 / Planned R&D investment of approximately EUR 1 billion in 2017 / R&D efforts to bring 15 new products to farmers between 2017 and 2020 / Strong focus on innovation and sustainability / Commitment to transparency (Source: Bayer Company News)
Source: Bayer Company News - September 19, 2017 Category: Pharmaceuticals Source Type: news
Crop Science Division of Bayer well positioned to fulfill future customer, market and societal needs
Global seed and crop protection market will continue to grow / Business in Brazil expected to return to normal in 2018 / Progress being made in planned Monsanto acquisition / Anticipated closing in early 2018 / Planned R&D investment of approximately EUR 1 billion in 2017 / R&D efforts to bring 15 new products to farmers between 2017 and 2020 / Strong focus on innovation and sustainability / Commitment to transparency (Source: Bayer Company News)
Source: Bayer Company News - September 19, 2017 Category: Pharmaceuticals Source Type: news
Bayer receives positive CHMP opinion for rivaroxaban 10 mg once daily for the extended prevention of venous thromboembolism (for specialized target groups only)
Rivaroxaban 10 mg once daily significantly reduces the risk of recurrent venous thromboembolism compared with aspirin 100 mg once daily after at least six months of standard anticoagulation therapy / Positive CHMP Opinion is based on data from the Phase III EINSTEIN CHOICE study / Final European Commission decision expected by November 2017 (Source: Bayer Company News)
Source: Bayer Company News - September 15, 2017 Category: Pharmaceuticals Source Type: news
Bayer receives FDA approval for Copanlisib in adults with relapsed follicular lymphoma after two prior systemic therapies (for specialized target groups only)
Accelerated approval based on overall response rate (ORR) of 104 adult patients with relapsed follicular lymphoma (FL) from the Phase II CHRONOS-1 study / Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial / Copanlisib achieved a 59% ORR in patients with relapsed FL [n=104 (95%CI 49,68)] / First approval of an intravenous phosphatidylinositol-3-kinase (PI3K) inhibitor (Source: Bayer Company News)
Source: Bayer Company News - September 14, 2017 Category: Pharmaceuticals Source Type: news
